SEARCH

SEARCH BY CITATION

References

  • 1
    Sanderson RJ, Ironside JA. Squamous cell carcinomas of the head and neck. Br Med J 2002; 325: 8227.
  • 2
    Vokes EE, Weichselbaum RR, Lippman SM, Ki Hong W. Head and neck cancer. N Engl J Med 1993; 328: 18494.
  • 3
    Pivot X, Niyikiza C, Poissonnet G, Dassonville O, Bensadoun RJ, Guardiola E, Foa C, Benezery K, Damard F, Thyss A, Schneider M. Clinical prognostic factors for patients with recurrent head and neck cancer: implications for randomized trials. Oncology 2001; 61: 197204.
  • 4
    Nagase H, Woessner JFJr. Matrix metalloproteinases. J Biol Chem 1999; 274: 214914.
  • 5
    Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990; 1: 99106.
  • 6
    Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 113549.
  • 7
    Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990; 9: 289303.
  • 8
    Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001; 11: 14352.
  • 9
    John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001; 7: 1423.
  • 10
    Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999; 103: 123741.
  • 11
    Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998; 186: 518.
  • 12
    Väisänen A, Kallioinen M, von Dickhoff K, Laatikainen L, Höyhtyä M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein: a new prognostic marker in uveal melanoma? J Pathol 1999; 188: 5662.
  • 13
    Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998; 83: 115362.
  • 14
    Sienel W, Hellers J, Morresi-Hauf A, Lichtinghagen R, Mutschler W, Jochum M, Klein C, Passlick B, Pantel K. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003; 103: 64751.
  • 15
    Laack E, Köhler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, Niestroy A, Dahlmann N, Peters A, Berger J, Fiedler W, Hossfeld DK. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002; 13: 15507.
  • 16
    Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer: TIMP-1 as a prognostic marker. Anticancer Res 2000; 20: 13116.
  • 17
    Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L. Plasma MMP-9 (92 kDa-MMP-9) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 2003; 106: 74551.
  • 18
    Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, Kakeji Y, Sugimachi K. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 1997; 17: 22538.
  • 19
    Charous SJ, Stricklin GP, Nanney LB, Netterville JL, Burkey BB. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol 1997; 106: 2718.
  • 20
    Kawamata H, Uchida D, Hamano H, Kimura-Yanagawa T, Nakashiro K, Hino S, Omotehara F, Yoshida H, Sato M. Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int J Oncol 1998; 13: 699704.
  • 21
    Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinase and oral cancer. Oral Oncol 1999; 35: 22733.
  • 22
    Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res 2004; 10: 31106.
  • 23
    Ikebe T, Shinohara M, Takeuchi H, Beppu M, Kurahara S, Nakamura S, Shirasuna K. Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin Exp Metastasis 1999; 17: 31523.
  • 24
    Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, Takeuchi H, Shirasuna K. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 1999; 21: 62738.
  • 25
    Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol 1995; 104: 67884.
  • 26
    International Union Against Cancer. TNM classification of malignant tumors. New York: Wiley-Liss, 1997. 749.
  • 27
    Shanmugaratnam K, in collaboration with Sobin LH and pathologists in 8 countries. Histological typing of tumours of the upper respiratory tract and ear, 2nd ed. Berlin: Springer-Verlag, 1991. 749.
  • 28
    Nikkari ST, Höyhtyä M, Isola J, Nikkari T. Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996; 149: 142733.
  • 29
    Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur J Haematol 2002; 69: 20512.
  • 30
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 45781.
  • 31
    Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001; 7: 31139.
  • 32
    Yorioka CW, Coletta RD, Alves F, Nishimoto IN, Kowalski LP, Graner E. Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients. Int J Oncol 2002; 20: 18994.
  • 33
    Homer JJ, Greenman J, Stafford ND. Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol 2002; 27: 327.
  • 34
    Homer JJ, Greenman J, Drevs J, Marme D, Stafford ND. Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma. Head Neck 2002; 24: 7738.
  • 35
    Chow V, Yuen AP, Lam KY, Ho WK, Wei WI. Prognostic significance of serum p53 protein and p53 antibody patients with surgical treatment for head and neck squamous cell carcinoma. Head Neck 2001; 23: 28691.
  • 36
    Ranuncolo SM, Matos E, Loria D, Vilensky M, Rojo R, Bal de Kier Joffe E, Puricelli LI. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer 2002; 94: 148391.
  • 37
    Kawata R, Shimada T, Maruyama S, Hisa Y, Takenaka H, Murakami Y. Enhanced production of matrix metalloproteinase-2 in human head and neck carcinomas is correlated with lymph node metastasis. Acta Otolaryngol 2002; 122: 1016.
  • 38
    Riedel F, Gotte K, Schwalb J, Bergler W, Hormann K. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000; 17: 1099105.
  • 39
    Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, Baba M, Shiba M. Elevated levels of circulating plasma matrix metalloproteinase-9 in non-small cell lung cancer patients. Clin Cancer Res 1999; 5: 14953.
  • 40
    Tutton MG, George ML, Eccles SA, Burton S, Swift RI, Abulafi AM. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 2003; 107: 54150.
  • 41
    Riedel F, Gotte K, Schwalb J, Hormann K. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma. Anticancer Res 2000; 20: 30459.
  • 42
    Kuropkat C, Plehn S, Herz U, Dunne AA, Renz H, Werner JA. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. Anticancer Res 2002; 22: 22218.